{"id":"raltegravir-and-zidovudine","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Lipoatrophy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This combination targets two critical steps of HIV replication. Raltegravir inhibits the integrase enzyme, preventing the viral genome from integrating into the host chromosome. Zidovudine inhibits reverse transcriptase, blocking the conversion of viral RNA into DNA. Together, they provide complementary antiretroviral activity against HIV-1.","oneSentence":"Raltegravir is an integrase inhibitor that blocks HIV integration into host DNA, while zidovudine is a nucleoside reverse transcriptase inhibitor that prevents HIV RNA conversion to DNA.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T06:30:03.594Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection (treatment)"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT05502341","phase":"PHASE2, PHASE3","title":"Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-08-16","conditions":"HIV-1-infection","enrollment":689},{"nctId":"NCT07080138","phase":"","title":"Research on the Psychological Status of Patients With HIV-1 Infection","status":"NOT_YET_RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-08-01","conditions":"HIV-1-infection, Anxiety Depression","enrollment":500},{"nctId":"NCT04012931","phase":"PHASE2","title":"A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-07-18","conditions":"HIV","enrollment":26},{"nctId":"NCT00955968","phase":"PHASE4","title":"IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2010-01-01","conditions":"HIV Infection","enrollment":1653},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT01352715","phase":"PHASE3","title":"Study of Options for Second-Line Effective Combination Therapy (SELECT)","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2012-03-13","conditions":"HIV-1 Infection","enrollment":515},{"nctId":"NCT03394196","phase":"NA","title":"RESIST-2: 2nd-line ART for HIV-2 Infection","status":"TERMINATED","sponsor":"University of Washington","startDate":"2018-07-04","conditions":"HIV-2 Infection","enrollment":152},{"nctId":"NCT01618305","phase":"PHASE4","title":"Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission","status":"COMPLETED","sponsor":"Westat","startDate":"2013-09-05","conditions":"HIV Infections","enrollment":408},{"nctId":"NCT02150993","phase":"PHASE2, PHASE3","title":"First-Line Treatment for HIV-2","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2016-01-26","conditions":"HIV-2 Infection","enrollment":210},{"nctId":"NCT02655471","phase":"EARLY_PHASE1","title":"Effect of Raltegravir in Patients With Acute Tropical Spastic Paraparesis - Human T-Lymphotropic Virus 1 Infection","status":"COMPLETED","sponsor":"Universidad Peruana Cayetano Heredia","startDate":"2017-07-01","conditions":"HTLV-I Infections, Tropical Spastic Paraparesis","enrollment":10},{"nctId":"NCT00708162","phase":"PHASE3","title":"Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-07","conditions":"HIV Infection","enrollment":724},{"nctId":"NCT01908660","phase":"","title":"Hepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life Conditions","status":"COMPLETED","sponsor":"Valme University Hospital","startDate":"2007-01","conditions":"Human Immunodeficiency Virus, Hepatitis B, Chronic, Hepatitis C, Chronic","enrollment":192},{"nctId":"NCT01565889","phase":"PHASE1, PHASE2","title":"Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-03","conditions":"Hepatitis C, HIV","enrollment":52},{"nctId":"NCT00624195","phase":"PHASE2, PHASE3","title":"Clinical Trial of CNS-targeted HAART (CIT2)","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2007-03","conditions":"HIV Infections","enrollment":59},{"nctId":"NCT00666055","phase":"","title":"Sex, Aging and Antiretroviral Pharmacokinetics","status":"COMPLETED","sponsor":"Kristine Patterson, MD","startDate":"2008-03","conditions":"HIV Infections","enrollment":11},{"nctId":"NCT00765271","phase":"PHASE1","title":"Abacavir Pharmacokinetic Study in the Absence/Presence of Darunavir/Ritonavir or Raltegravir in HIV-infected Subjects","status":"COMPLETED","sponsor":"St Stephens Aids Trust","startDate":"2008-05","conditions":"HIV","enrollment":29}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[{"date":"20100917","type":"ORIG","sponsor":"CHARTWELL RX","applicationNumber":"ANDA079025"},{"date":"20140103","type":"SUPPL","sponsor":"CHARTWELL RX","applicationNumber":"ANDA079025"},{"date":"20200820","type":"SUPPL","sponsor":"CHARTWELL RX","applicationNumber":"ANDA079025"},{"date":"19990406","type":"SUPPL","sponsor":"FOSUN PHARMA","applicationNumber":"ANDA086173"},{"date":"19810828","type":"ORIG","sponsor":"FOSUN PHARMA","applicationNumber":"ANDA086173"},{"date":"19830516","type":"SUPPL","sponsor":"FOSUN PHARMA","applicationNumber":"ANDA086173"},{"date":"20001128","type":"SUPPL","sponsor":"FOSUN PHARMA","applicationNumber":"ANDA086173"},{"date":"19880726","type":"SUPPL","sponsor":"FOSUN PHARMA","applicationNumber":"ANDA086173"},{"date":"19830516","type":"SUPPL","sponsor":"FOSUN PHARMA","applicationNumber":"ANDA086173"},{"date":"20000403","type":"SUPPL","sponsor":"FOSUN PHARMA","applicationNumber":"ANDA086173"},{"date":"20111221","type":"ORIG","sponsor":"HOSPIRA INC","applicationNumber":"ANDA090653"},{"date":"20150902","type":"SUPPL","sponsor":"HOSPIRA INC","applicationNumber":"ANDA090653"},{"date":"20150902","type":"SUPPL","sponsor":"HOSPIRA INC","applicationNumber":"ANDA090653"},{"date":"20120626","type":"ORIG","sponsor":"PADAGIS ISRAEL","applicationNumber":"ANDA090979"},{"date":"20150518","type":"SUPPL","sponsor":"PADAGIS ISRAEL","applicationNumber":"ANDA090979"},{"date":"20150903","type":"SUPPL","sponsor":"PADAGIS ISRAEL","applicationNumber":"ANDA090979"},{"date":"20250620","type":"SUPPL","sponsor":"XIROMED","applicationNumber":"ANDA206120"},{"date":"20170912","type":"ORIG","sponsor":"XIROMED","applicationNumber":"ANDA206120"}],"publicationCount":85,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["\"Raltegravir\"","\"Zidovudine\""],"phase":"marketed","status":"active","brandName":"\"Raltegravir\" and \"Zidovudine\"","genericName":"\"Raltegravir\" and \"Zidovudine\"","companyName":"Universidad Peruana Cayetano Heredia","companyId":"universidad-peruana-cayetano-heredia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Raltegravir is an integrase inhibitor that blocks HIV integration into host DNA, while zidovudine is a nucleoside reverse transcriptase inhibitor that prevents HIV RNA-to-DNA conversion; together they provide dual antiretroviral activity. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}